

DISCLAIMER

Information provided on the website of iFabric Corporation (the "Company") including the reports posted thereto contains forward-looking statements that reflect management's current expectations relating to matters such as future financial performance and operating results of the Company.

Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans, and allow investors and others to better understand the Company's anticipated financial position, results of operations, and operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

Certain statements may constitute forward-looking statements, including but not limited to, statements regarding the expected benefits and results of the Company's initiatives and other statements concerning management's current expectations relating to possible or assumed future prospects and results, the Company's strategic goals and priorities, its actions and the results of those actions and the economic and business outlook for the Company. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "estimate", "plan", "can", "could", "should", "would", "outlook", "forecast", "anticipate", "aspire", "foresee", "continue", "ongoing" or the negative of these terms or variations of them or similar terminology. Forward-looking statements are based on the reasonable assumptions, estimates, analyses, beliefs and opinions of management, made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable at the date that such statements are made.

By their very nature, forward-looking statements require management to make assumptions and are subject to inherent risks and uncertainties, which give rise to the possibility that the Company's assumptions, estimates, analyses, beliefs and opinions may not be correct and that the Company's expectations and plans will not be achieved. Although the Company believes that the forward-looking information in the statements are based on information, assumptions and beliefs that are current, reasonable and complete, such information is necessarily subject to a number of factors that could cause actual results to differ materially from management's expectations and plans as set forth in such forward-looking statements. Some of the factors, many of which are beyond the Company's control and the effects of which can be difficult to predict, include but are not limited to, changes in economic and market conditions and other risks and uncertainties discussed in the Company's materials filed with the Canadian securities regulatory authorities from time to time as well as the Company's other public filings, available on the SEDAR (System for Electronic Document Analysis and Retrieval) website at www.sedar.com. Management cautions that the foregoing list of important factors and assumptions are not exhaustive and other factors could also adversely affect the Company's initiatives.

Investors and other readers are urged to consider the foregoing risks, uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements and information contained in the Reporting are based on certain factors and assumptions as of the date hereof. The Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by it or on its behalf, to reflect new information, future events or otherwise, except as is required by applicable securities laws.

COMPANY HIGHLIGHTS

INTELLIGENT FABRICS THAT ADDRESS UNMET CONSUMER AND MEDICAL NEEDS

- Patented antimicrobial technologies for performance apparel
- Antiviral treatment solution has been 3rd party tested against COVID-19 and several other viruses and bacteria
- Sustainable water repellent, moisture wicking and UV protection technologies

ADVANCED CLAIM US EPA APPROVAL WILL BE MAJOR CATALYST

Pending additional US EPA claim registration for our anti-viral technology would create a step change in demand with current customers and new clients

GLOBAL PANDEMIC - NEW CONSUMER TRENDS CREATE MASSIVE UPSIDE POTENTIAL

\$9M annualized revenue run rate does not reflect pipeline for intelligent fabric technologies

MAJOR BRAND PARTNERS

Under Armour, Careismatic Brands, Lululemon, Walmart, Target, and The North Face are among our current top brand partners

MANAGEMENT ALIGNED

Management ownership is 75%+ of the Company

MANAGEMENT



HYLTON KARON President & CEO

Graduated from Philadelphia University with a BSC degree in textile marketing and management, and now has over 35 years of experience in product development and marketing. Hylton's creative ability has resulted in the development of many successful and patented products which are sold both in North America and internationally.



GIANCARLO BEEVIS President & CEO | IFTNA

A graduate with an Honours B.A. from York University, Giancarlo has been involved with the company for 15 years, contributing expert knowledge and is instrumental in the brand development of Intelligent Fabric Technologies North America. Giancarlo oversees the strategic direction of IFTNA and the development of products, brands and technologies.



HILTON PRICE Group Chief Financial Officer

A Chartered Professional Accountant with over 40 vears of experience covering a variety of industries and business. Hilton has been involved in most elements of the group's strategic planning and is responsible for financial oversight since the groups inception.



JASON GARAY Chief Science Officer | IFTNA

Mr. Garay is the VP of Analytics and Informatics at Cancer Care Ontario (CCO). Jason was previously the Director, Communicable Disease Prevention and Control at Public Health Ontario. He is an Adjunct Professor at the University of Toronto and holds an MHSc in Community Health and Epidemiology, a BASc in Occupational and Public Health, and a BSc (Honours) in Statistics and Psychology.

BOARD OF DIRECTORS

Dr. Mark Cochran

PhD Chairman Dr. Cochran is Executive Director of Johns Hopkins Medicine. His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Mark Greenspan

CA, CBV Director

Mr. Greenspan was CFO of The Medipattern Corporation from September 2002 until February 2010. Prior to that, he spent 18 years at Scotiabank in various executive capacities. Prior to joining Scotiabank, he spent 8 years at KPMG where he specialized in mergers and acquisitions.

Cameron Groome

Director

Cameron has served on the Microbix Board of Directors and Advisory Committee since 2012, and was appointed CEO in 2017. He has more than 25 years of experience in senior life sciences and finance roles and has been an executive, director, and advisor for public and private companies.

Hylton Karon

Director

Mr. Karon is the President and CEO of iFabric Corp.

Hilton Price

Director

Mr. Price is the CFO of iFabric Corp.

Giancarlo Beevis

Director


Mr. Beevis is the President and CEO of IFTNA, a division of iFabric Corp.

CAPITAL STRUCTURE

TSX LISTED, SYMBOL: IFA OTC: IFABF

iFabric Corp. TSX Exchange | Aug 5, 2020, 8:41 AM EDT | Real-time price IFA \$ 5.30 ET CHANGE 0.04 (0.7605%) VOLUME 2,300

Click Here for Real-Time Stock Price



Current Price	\$5.30	Market Capitalization	\$139.9M
Shares Outstanding (Basic)	26.4M	Avg. Daily Volume (last 12 months)	9,072
(Fully Diluted)	28.2M	Available Cash and Line of Credit	\$6.0M
52 Week High	\$7.87	Long Term Debt	\$1.3M
52 Week Low	\$0.52	Management Ownership	>75%

TWO DIVISIONS

Socially responsible fabric technologies as well as intimates and and wardrobe solutions.



INTELLIGENT FABRIC TECHNOLOGIES (NORTH AMERICA) INC. (IFTNA)

- Revenue Stream #1 Developed a range of performance additives for textiles. Including antimicrobial and antiviral textiles as well as solutions for medical, athletic, military, consumer & corporate apparel, bedding, linens and other categories.
- Lab testing confirms our new PROTX2°AV solution is efficacious against COVID-19, Coronavirus, MRSA, Staph, C-Diff, VRE, E. Coli, Norovirus, H1N1, and Influenza A & B.
- Revenue Stream #2 Manufacturing private label performance apparel utilizing key technologies to meet consumer demand for performance textiles.
- Revenue Stream #3 Launching own brand of performance and travel apparel as well as own brand of personal protective equipment in the near term.



COCONUT GROVE INTIMATES

- Coconut Coconut Grove Intimates is where high-style and comfort meets design and functionality. Over the last 35 years, our team of designers have been developing and supplying the fashion industry with unique and superior intimate and sleepwear apparel collections that reach global markets. Since our inception, we have developed many utility and design patents setting our offering apart from the rest.
- Revenue Stream #1 Private label in house brand sold online and in brick and mortar stores.
- **Revenue Stream #2** Supply brands and distribute products for some of the most well known intimates brands globally.

IFTNA TECHNOLOGY **PORTFOLIO**

IFTNA has developed a number of products that are partnered with household brands:

- PROTX2*AV Antiviral, antibacterial & anti-odour
- PROTX2® Antibacterial, antimicrobial & anti-odour
- **REPELTX ECO PLUS** Fluorine free water repellent
- **OMEGA*** Accelerated joint & muscle recovery
- **TEMP+x** Thermo and cooling regulator
- **ECOTX** Metal-free antimicrobial
- **DREAMSKIN** Encourages healthy & hydrated skin

- **APOLLO** Body odour neutralizer
- **DRIFORCE** Evaporation enhancement
- **ENGUARD** Insect repellent
- **DRYTX** Moisture wicking technology
- **UVTX** Superior UV protection
- **imprint** Wicks away moisture using fabric gateways exposing logos and patterns











IFTNA BRAND PARTNERS







































































THE PROBLEM

A GLOBAL PANDEMIC

- Amid the COVID-19 crisis, the global market for Antimicrobial Textiles estimated at US\$8.5 Billion in the year 2020, is projected to reach a revised size of US\$11.5 Billion by 2027
- The U. S. Accounts for Over 29.4% of Global Market Size in 2020. While China is Forecast to Grow at a 4.2% CAGR for the Period of 2020-2027

HEALTHCARE ASSOCIATED INFECTIONS (HAI'S)

- Now one of the top 6 leading causes of deaths in the developed world (CDC, NIH)
- Textiles are a major source of HAIcausing pathogens and yet there is no effective way to keep them free of these pathogens during use
 - 60% of standard medical uniforms are contaminated with up to 4 potentially infectious bacteria
- 92% of hospital privacy curtains are contaminated with multiple infectious bacteria
- 100,000 deaths from hospital HAI's last year

CONSUMER DESIRE

- The consumer desire for ecofriendly sustainable controlled odour solutions that allow for more wear and less washing
 - Bacteria can easily survive average drying cycle of minutes and can live on bric for up to 2-3 weeks

www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/ www.ncbi.nlm.nih.gov/pmc/articles/PMC4180417/ www.ncbi.nlm.nih.gov/pubmed/22464039

PROTX2®


THE BREAKTHROUGH

PROTX2° is a breakthrough in antibacterial, antimicrobial and anti-odour protection. When treated, each fiber is fundamentally transformed through PROTX2°'s technology providing proprietary unrivalled protection.

PROTX2° in different dosages can be used in two distinct ways:

HEALTHCARE, HOSPITALITY
& FOOD SERVICE
as an antimicrobial, antibacterial,
and antiviral agent

ATHLEISURE & SPORTSWEAR as an anti-odour agent



PRQTX2®

METAL-FREE ANTIVIRAL, ANTIBACTERIAL & ANTI-ODOUR AGENT

- PROTX2°AV is the world's first antiviral textile technology proven to kill greater than 99.9% of SARS-COV-2 (COVID-19) in 10 minutes.
- An effective, medical-grade solution for reducing the spread of nosocomial infections on soft and hard surfaces.

PROTX2®AV is the world's first antiviral, antibacterial and anti-odour technology to be registered for kill claims with the US EPA.

- It is 3rd party certified by independent laboratories to be an incredibly effective broad spectrum antiviral, antibacterial and anti-odour technology.
- Our recent lab testing has shown PROTX2°AV's efficacy against COVID-19 and Coronaviruses. It has also been tested against MRSA, Staph, C-Diff, VRE, E. Coli, Norovirus, H1N1, and Influenza A & B.
- 2 Clinical trials pending start in California: 400 nurses wearing PROTX2°AV treated scrubs, swabbed before and after shifts.
- The PROTX2°AV solution is already in use by one of the largest Scrub Manufacturers in the United States.



PRIVATE BRAND **LAUNCHES**



Underit* is IFTNA's privately owned brand, that specializes in developing forward thinking technology infused performance and travel apparel, with PROTX2® as the host of all our other technologies.

We have designed, developed and patented an extensive range of mens, womens, and kids products listed below:


Underwear | Sports Bras | Base Layer | Tights/ Leggings | Shirts & Tops | Compression | Athleisure

For launch year we have an expected revenue of \$5M with a 20-25% margin. Year 2 is an expected \$10M in revenues with 40-55% margin.



Frontline* is IFTNA's healthcare driven privately owned brand, specializing in PROTX2* AV treated personal protective equipment including:

Masks | Gloves | Gowns | Other Necessary PPE











OPPORTUNITY

brand supply chain

- 2. Design manufacturing supply of finished product
- 3. Design manufacturing supply of finished product
- 4. Launch of own brand and travel apparel (Underit)

ADDRESSABLE MARKET

TOTAL MARKET SIZE: \$106+ Billion1

- 1. \$2 Billion (**Margin** 35%)
- 2. \$4 Billion (Margin 40-50%)
- 3. \$200 Million (**Margin** 40%)
- 4. \$1 Billion (Margin 50+%)

APPLICATIONS

- *Underwear

MEDICAL APPAREL

PERFORMANCE APPAREL

- 2. Design manufacturing supply of owned brand personal protective equipment and

TOTAL MARKET SIZE: \$10+ Billion²

- 1. \$4 Billion (**Margin** 45%)
- 2. \$4 Billion (**Margin** 45%)

- *Surgical Gowns
- *Surgical Gloves

MEDICAL AND HOME TEXTILES

- 2. Design manufacturing supply of finished home textile products

TOTAL MARKET SIZE: \$10+ Billion³

- 1. \$500 Million (**Margin** 45%)
- 2. \$500 Million (Margin 45%)

The worldwide market for performance apparel is expected to grow at a CAGR of roughly 9.5% over the next five years and will reach \$10,600 million US\$ in 2024 from \$6,140 million US\$ in 2019, according to the latest GIR (Global Info Research) study. ²Scrubs are a \$10 billion industry in the United States and \$60 billion worldwide. Thousands of medical professionals enter the workforce every year.

COCONUT GROVE INTIMATES

Over the last 30 years, we have continued to stay on top of market trends to design, develop and supply the fashion industry with unique solution bras and bra accessories for every possible occasion. CGI is part of a niche market with aging competition and room for exponential growth.



25+ YEARS OF PROFITABILITY

Over 25 years of profitable operations with gross margins over 50%.



PRIVATE LABEL

Distribution across Canada, USA and the UK with over 1.000 different product offerings.



PATENTS

Innovative registered patents as well as new patent pending products.



















FLAGSHIP RETAILERS









FINANCIALS AND PROJECTIONS


IFABRIC GROUP

IF TECHNOLOGIES NA

COCONUT GROVE INTIMATES







2018: \$15.1 M

2019: \$10.4 M

2020: \$12 M

2021: \$29 M

2022: \$56 M

2023: \$78 M

2020: \$9 M

2021: \$25 M

2022: \$50 M

2023: \$70 M

2020: \$3M

2021: \$4 M

2022: \$6 M

2023: \$8 M

HISTORIC EARNINGS IFABRIC GROUP

	2018	2019			
Revenue	15,121,370	10,435,348			
Adjusted EBITDA*	1,783,260	-1,339,227			
Net Earnings (Loss per share)					
Basic	0.035	-0.05			
Diluted	0.034	-0.05			

UPCOMING MILESTONES

US EPA ADVANCED CLAIM REGISTRATION

OWNED BRAND LAUNCH -UNDERIT® & FRONTLINE®

Underit* travel and performance apparel line expected to launch Spring 2021

Frontline* personal protective equipment brand expected to launch Q4 2020-Q1 2021

CLINICAL TRIALS WITH PROTX2® & REPELTX®

2 trials pending with 400 nurses in 2 major US hospital systems utilizing PROTX2° and RepelTX* technologies

EXPANDING CUSTOMER BASE AND RENEWED CUSTOMERS

Large pipeline of new customers and indications of reorders from clients

APPENDIX

PATENT PORTFOLIO

Our portfolio of innovative patents answer today's market trends.

PATENT PENDING

PROTX2® AVGuard


Our proprietary laundry additive with antiviral, antibacterial and antiodour properties.



PATENT PENDING

SLOTTED MASK

Triple layer constructed protective mask.



PATENT PENDING

PROTX2° AV

Our antiviral, antibacterial and anti-odour agent.



PATENT PENDING

HAT MASK


A protective mask designed with a clip feature to attach to hats.



PATENT PENDING

MESH SLING

Using the most advanced construction techniques and materials, we've created a mesh sling that provides optimum support and comfort.



PATENTED

BREAST LIFT

The perfect braless solution with a unique tab design providing customizable lift and a contoured natural shape.



PATENT PENDING

2-SIDED FLY

Our 2-sided patented fly design caters to the wearer's needs, whether they are left or right handed, while providing all day comfort and support.



PATENT PENDING

REVERSIBLE WING BRA

1 bra with 2 colour choices (nude and black) designed with double-sided silicone wings and dyed to match wing covers.



IN THE MEDIA

OMPA



Full Fast Company Article

3 Red-Hot TSX Stocks That Can

specifically: said Beeves, who is the CEO of the Canadian Isocret. firm Istelligent Tabers: Technologies North America (IPTNA), "We weren't interested in sesting it against the human occomovirus, which our competitures were doing, because to us it didn't have value. We wanted to deal with the pandersic."



Full Forbes Article Underarmour Website



Full Zozo Article



Full NST Article

00000

0 O ш 0 ш



Full Motley Fool Article



Canadian biotech company says its anti-viral clothing kills 99.9 per cent of coronavirus Well-wides Austral 2020 10 MPH EDI SHARE [] 113 9 di [] of COVID-IP protection; antiveral clothing made to protect against the virus. S EΚ CEO Grandario Beevis first sow the need for anti-viral fabric 10 years ago, when there was an outbreak of norovirus on cruise ships. If the person folding the naplan into a swan — or whaten it was supposed to look like — on your buffer table had norows an [ther] hands. It was transmitting when you went to wipe your mouth," he told NewsNight by CTV. News, available on the streaming app Quits. Newsletter sign-up: Get The COVID-19 Brief sent to your inbox

ON NEWS

THE CTV NEWS APP DOWNLOAD NEWS, ANYTIME, ANYWHERE NEWS MENU VIDEO WEATHER Bill Morneau Resigns As Finance Minister Online Learning More Popular Than Expecte Trying To Rebuild In Beirut CFL Cancels 2020 Season Call For Employer-Provided Sick Leave

⋛

O

Z

Full Everyday Health Article

Full CTV News Article

Full CTV News Ottawa Article

IN THE MEDIA



An Ontario-based performance apparel company has developed an antiviral fabric treatment that it says effectively destroys COVID-19 within 10 minutes.

Fast Company reports that Intelligent Fabric Technologies North America's

Full ASI Central Article

ш S S ш S

BUSINESS INSIDER

This week, Under Armour debuted the Sportsmask. The \$30 mask is meant to be more breathable and comfortable than most personal protective equipment while still helping prevent the spread of


The mask sold out in less than an hour, Under Armour CEO Patrik Frisk said on Twitter on Thursday. More are expected to become

The Sportsmask is made with three layers, matching current recommendations from the US Centers for Disease Control and Prevention. Its moldable nose-bridge and air pockets to provide structure are designed to make the mask more breathable, while antimicrobial PROTX2 is supposed to inhibit the growth of bacteria.

Face coverings are thought to help keep infected people from spreading the novel coronavirus through respiratory droplets.

Under Armour began manufacturing face masks for healthcare and community organizations in mid-March, as the US scrambled to keep up with demand during the coronavirus pandemic. Under Armour's founder, Kevin Plank, was involved with creating designs for a mask made for athletes.

Full Business Insider Article



Full LS:N Global Article

ΣΟ @engineering.com NEW Ŭ Ü ERIN

Antiviral Clothing Aims to Shield Against COVID-19

PROTX2 AV chemical disrupts the virus's ability to replicate.

2020 is the year we clamored to buy consumer products that we would never have given a second thought to previously. Disinfectant wipes and hand sanitizer? Yes, please. A transparent face mask? Add to cart.

As scientists race to develop a vaccine that will finally put the COVID-19 era to an end, a Canadian biotech company has introduced yet another commodity to safeguard against infection: antiviral fabric.

 ${\bf Toronto-based} \ \underline{\bf Intelligent} \ \underline{\bf Fabric} \ \underline{\bf Technologies} \ \underline{\bf (North} \ \underline{\bf America)} \ \underline{\bf Inc.}$ (IFTNA), a subsidiary of iFabric Corp., has innovated a chemical treatment for textiles that has proven effective against the SARS-CoV-2 virus. The first line of COVID-impairing apparel is projected to be $\,$ available this fall.

Antimicrobial fabrics are not a new concept, IFTNA has been creating antibacterial chemical treatments for textile firms serving the medical,

Full Engineering.com Article

THANK YOU!



HYLTON KARON



President & CEO





905.752.0566 x201



905.752.0567

HILTON PRICE



Chief Financial Officer







905.752.0567

GIANCARLO BEEVIS



President & CEO | IFTNA



✓ GC@iftna.com



647.225.4426



4 905.752.0566 x202



9 905.752.0567

INVESTOR RELATIONS:

TINA BYERS

905.330.3275 tina@adcap.ca

JEAN-FRANCOIS DUBÉ (QUEBEC)

514.233.9551 jfdube@mac.com

GARY PERKINS

416.882.0020 garyperkins@rogers.com